MGMT and glioblastoma: Furthermore, an assessment of the relationship between the CDKN1A c.93C > A genotype and demographic as well as clinicopathological characteristics of GBM patients was conducted, encompassing factors such as IDH1 gene status and MGMT promoter methylation status (as demonstrated in Table 3).